shaunt 𒌐

182 posts

shaunt 𒌐

@shaunt___

biotech // healthcare

Los Angeles, CA Katılım Ocak 2019

1.5K Takip Edilen2K Takipçiler

shaunt 𒌐@shaunt___·5h

Totally fair framing. I agree there is a physiological limit to how much fat can be oxidized, and the leaner someone gets, the more careful you have to be with rate of loss. My only point is that this is different from saying the current retatrutide data proves disproportionate muscle loss versus tirzepatide. I do not think the evidence is that clean. But on the real-world side, we are aligned. If someone is pushing for maximal speed, muscle retention has to become a first-order priority.

English

341

Greg O'Gallagher@gregogallagher·5h

@shaunt___ Mechanistically. Body has limit to how much fat oxidation in a day. Leaner you are the lower that limit is. Pushin deficit larger with new pathway comes at risk of muscle loss. Can it be managed yes. But chasing faster weight loss not good.

English

2.8K

Greg O'Gallagher@gregogallagher·5h

Literally everyone was wrong!!!! Retatrutide causes more muscle loss than tirzepatide. This isn’t speculation. The clinical trials prove it. Tirzepatide: 75% of weight lost is fat. 25% is lean mass. Retatrutide: only 62-69% of weight lost is fat. Up to 38% is lean mass. Here’s why. Retatrutide activates a third receptor, glucagon. Glucagon amplifies the energy deficit by increasing thermogenesis and driving your body to burn more. More deficit sounds good. But a larger deficit always comes with a price. The bigger the deficit, the harder your body raids muscle for fuel. And if you’re already lean? The risk multiplies. At low body fat there’s less fat available to burn. Your body turns to muscle faster. Tirzepatide is the smarter tool for anyone serious about their physique. More weight lost as fat. Less muscle sacrificed to get there.

English

178

30.9K

shaunt 𒌐@shaunt___·9h

The issue is messaging, not science. When the message is that a peptide is synonymous with GLP-1s/steroids/performance enhancing drugs that are mostly attainable through black and grey markets, it devalues the current innovation that my team and others are doing in disrupting the biopharma landscape

English

Meltem Demirors@Melt_Dem·1d

the replies to this are fascinating i'm frankly surprised that so many people are anti choice. feels strangely similar to the backlash against Bitcoin. i am strongly in favor of enabling more degrees of freedom for individuals in the face of increasing government overreach 🫡

Meltem Demirors@Melt_Dem

my only angel investment last year was a peptide company PEOPLE WANT TO HAVE AGENCY OVER THEIR HEALTH i couldn’t be more enthusiastic about the current trend of self instructed health maxxing - let the people decide

English

112

16.7K

shaunt 𒌐@shaunt___·9h

@PeptideList @BasedBiohacker the landscape is a lot more accelerationist now, admin is taking great strides

English

ThePeptideList@PeptideList·10h

I am under the impression/assumption/speculation this new administration is working in good faith to change this dynamic. Peptides are literally a short or long chain of amino acids. This is not a controversial issue. Just lacks clear funding and guidance. By the way, still want to try moda-bromo, those were excellent write ups. Let me know if you want to get added to the list.

English

451

BasedBiohacker@BasedBiohacker·10h

big pharma strikes again. the systematic infection, like tentacles meddling with every single aspect of healthcare, research, media, policy, goes a lot deeper than most people realize. the lobbying is omnipresent.

ThePeptideList@PeptideList

The "evidence" argument on peptides is intellectually lazy and Eric Topol should know better. You have 730K followers. You're one of the most cited physicians alive. And the best you can do is "show me the evidence" like a med student who just discovered PubMed? You know exactly why the evidence doesn't exist: No patent = no pharma funding No FDA pathway = no required trials No grant money = no academic interest Meanwhile millions of people are using these compounds and clinicians are reporting real outcomes. That's signal. Dismissing it as "promotion" is the opposite of scientific curiosity. Fund the trials or stop pretending the absence of evidence is evidence of absence. That's not skepticism. That's just arrogance with a blue check.

English

3.1K

shaunt 𒌐@shaunt___·9h

@BerbarianWizard too many hop on exogenous before even attempting at improving their baseline It's become an instant gratification economy where the solution always seems external; education is SO important.

English

Jamal Dinkoui@BerbarianWizard·1d

PEDs are literally called performance-enhancing drugs for a reason. At the highest level, athletes use them only after optimizing everything : training, nutrition, lifestyle, recovery. They’re already in top shape, and PEDs are just a marginal edge to outperform others. Meanwhile, the average guy hopping on PEDs is overweight, sedentary, with poor diet and habits. In that context, they don’t fix anything, and often make things worse. Give testosterone to a fat person and you’re just increasing substrate for aromatase = more estrogen.

Abud Bakri MD@AbudBakri

Strategy vs tactic of health A lot of people focus on tactical health successes but overall have strategic failure They focus on buying the best version of creatine… but their workout regiment sucks They take am optimal multiblend of magnesium… but have terrible circadian habits They get labs regularly… but don’t have good protocol changes based on those labs Spend money on BPC-157… but don’t have a good personal trainer to help guide the recover List can go on and on Focus on the overall strategy, then add in the tactics

English

4.4K

shaunt 𒌐@shaunt___·22h

@Aleeexanderrrrr @lordsambrah

QAM

Alex RF@Aleeexanderrrrr·1d

Throw back to Miami 2002 when Federer hit this insane volley from the baseline 🤯

English

154

5.6K

364.7K

shaunt 𒌐@shaunt___·1d

@AbudBakri @0xexpt redactide just cleared tox studies

English

Abud Bakri MD@AbudBakri·1d

@0xexpt Shhh don’t mention redactamine publically

English

1.6K

Abud Bakri MD@AbudBakri·1d

Currently testing the peptides your fav influencer will be talking about in 2028

English

311

20.2K

shaunt 𒌐@shaunt___·1d

@morganamooo could all be distilled to one thing organically

English

shaunt 𒌐@shaunt___·1d

@stackapp @remedyplace RP is top tier for recovery and optimization, I’m sure it’ll be great

English

Stack@stackapp·1d

@shaunt___ @remedyplace Let me know how it is!

English

Stack@stackapp·1d

The moment compounding pharmacies start producing peptide pens at scale is when mainstream adoption goes from early majority to everyone. Peptides are already breaking into the mainstream. That is not the question anymore. The question is what removes the last barrier stopping the next wave of people from participating. And the answer is the needle. Most people will never reconstitute a vial, calculate a dose in micrograms, and inject themselves. That is a hard ask for anyone outside the biohacker community. Pre-filled pens solve that entirely. Remedy Place just launched a smart NAD pen in partnership with a UK-based pharmaceutical manufacturer. Ships direct to consumers without a prescription. $500 for a 30-day supply. Orders already coming in from LA, New York, Denver, South Florida. The founder is openly planning peptide pens next, specifically a BPC-157 and TB-500 blend, pending FDA action on Category 2 removals. When US compounding pharmacies start building this infrastructure at scale across the full peptide catalog, the addressable market expands by an order of magnitude. The person who would never touch a syringe will use a pen. That version of this space reaches hundreds of millions of people. We are closer to it than most realize.

English

774

shaunt 𒌐@shaunt___·1d

@shweta_ai he’s ineffeciencymaxxing

English

Shweta@shweta_ai·1d

he’s a 10 but he doesn’t use Claude Code

English

204

9.6K

shaunt 𒌐@shaunt___·1d

@Shilllin 🔒

QME

Alex 🥷@Shilllin·1d

Gm Happy Friday let’s get it

English

140

4.3K

shaunt 𒌐@shaunt___·1d

@GutOptimized never underestimate the power of n=1 the need to self-expirement comes at the necessity of finding out what works best for YOU

English

104

Ross 🧬🔬@GutOptimized·1d

Gut health is so fickle. Because for one person I might recommend fasting 18 hours and bring protein down. And another I might recommend never fast and eat high protein 3 x daily. One person I recommend to fibre max and another I take almost all fibre out. One I will tell to eat 300g carbs daily and another go carnivore. One person I tell you max dairy and another I tell to avoid. Don't feel bad if you think gut health info is confusing. Because it is. There's no one size fits all.

English

136

9.4K

shaunt 𒌐@shaunt___·1d

just been bymyselfmaxxing recently

English

290

shaunt 𒌐@shaunt___·1d

@AbudBakri Khavinson was truly ahead of his time He needs more appreciation for his work

English

651

Abud Bakri MD@AbudBakri·1d

Epithalon got put on the “do not compound” category 2 list in 2024 A lot of compound pharmacies decided to switch it out for Pinealon That little quirk led to this Pinealon wave, a compound that’s existed for a few decades lol. Completely ignored

English

133

9.9K

shaunt 𒌐@shaunt___·1d

@jeffinvenice @ouraring @chromeheartsusa you can only activate it at gjusta

English

9.3K

Jeff@jeffinvenice·1d

Oura x Chrome Hearts

English

115

3.5K

353.2K

shaunt 𒌐@shaunt___·1d

@hubermanlab Been advocating for this for some time, the disambiguation between GLP-1/peptide/PED along with the rising black and grey markets has had secondary effects with the perception of peptides

English

568

Andrew D. Huberman, Ph.D.@hubermanlab·1d

Public health discourse needs a nomenclature committee before this “peptides” thing gets out of hand. So many types, so much variation in evidence, so much at stake. Common language would really help everyone: pro and against.

English

414

54.3K

shaunt 𒌐 retweetledi

J. Edward Moreno@edwrdmoreno·2d

With certain peptides potentially getting off the FDA's no-compounding list, companies are rushing to establish legitimate supply chains. Meanwhile, search interest in the US for “peptides” has skyrocketed and now even surpassed “Ozempic.”